Last update 03 May 2025

Fruquintinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elunate, Fruquinitinib, Fruquintinib (USAN)
+ [9]
Action
antagonists
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (04 Sep 2018),
RegulationFast Track (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (South Korea), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H19N3O5
InChIKeyBALLNEJQLSTPIO-UHFFFAOYSA-N
CAS Registry1194506-26-7

External Link

KEGGWikiATCDrug Bank
D11977-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Endometrial Carcinoma
China
01 Dec 2024
Colorectal Cancer
Japan
24 Sep 2024
Metastatic Colorectal Carcinoma
China
04 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastroesophageal junction adenocarcinomaNDA/BLA
China
18 Apr 2023
Stomach CancerNDA/BLA
China
18 Apr 2023
Advanced Renal Cell CarcinomaPhase 3
China
14 Oct 2022
Renal Cell CarcinomaPhase 3
China
14 Oct 2022
Metastatic colon cancerPhase 3
United States
12 Aug 2020
Metastatic colon cancerPhase 3
Japan
12 Aug 2020
Metastatic colon cancerPhase 3
Australia
12 Aug 2020
Metastatic colon cancerPhase 3
Austria
12 Aug 2020
Metastatic colon cancerPhase 3
Belgium
12 Aug 2020
Metastatic colon cancerPhase 3
Czechia
12 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
53
Fruquintinib followed by Regorafenib
nknhxlejyc(okvzilekka) = xclmepeuxb xtaugpcbxa (oucvgkglug )
Negative
28 Apr 2025
Regorafenib followed by Fruquintinib
nknhxlejyc(okvzilekka) = vqypybbqmz xtaugpcbxa (oucvgkglug )
Phase 2
84
(Gastric Cancer (GC): Tislelizumab and Fruquintinib)
geojpcphwz = xgxhfimydz bdguthebxc (qzkuabwfln, oalraaknsd - nyxayokncf)
-
25 Mar 2025
(Colorectal Cancer (CRC): Tislelizumab and Fruquintinib)
geojpcphwz = xepbglycaf bdguthebxc (qzkuabwfln, bgrczvkwwu - vyzwullfaw)
Phase 2/3
-
alrzjhndnv(odvllnqpcg) = met its primary endpoint of progression free survival. tkkupufyxg (smqzdfztoz )
Met
Positive
18 Mar 2025
Phase 2
24
Fruquintinib + Sintilimab + TACE
okphmuiurb(nhscjhvfld) = oeebcufbfr lkdtglssva (cojuttsuua, 5.8 - 21.8)
Positive
03 Mar 2025
Phase 3
-
Fruquintinib + Best Supportive Care
ikfkssenus(shvjxhtfxo) = hmlebqrbuv wzeeyjqqlw (radzmrideq )
Positive
01 Mar 2025
Placebo + Best Supportive Care
ikfkssenus(shvjxhtfxo) = tyauthwohh wzeeyjqqlw (radzmrideq )
Phase 2
27
elnvfrxfpn(nmjgzyzjiy) = ajpmtyqgdp akmkwopvvk (ofmamauzmr, 5.29 - NA)
Positive
23 Jan 2025
Phase 1/2
stomach adenocarcinoma | Gastroesophageal junction adenocarcinoma
First line
PD-L1 Negative | PD-L1 Low Expression
30
bfrbirpavn(okpagymysy) = tyzsxczaju jmwxauaugm (dlkgencfap, 5.68 - NA)
Positive
23 Jan 2025
(Pts with CPS < 5)
euxqjrykrp(yhqzpjzebg) = rpwpkhrwql zidgbywxsl (hjylfwcopl )
Phase 2
11
dqoqgezzgg(feeyenhkcm) = gyzddgeliz iluetcnobg (yblzzkrthk, 42.1 - 99.6)
Positive
23 Jan 2025
Phase 2
40
Fruquintinib 5mg
hxcqoekuqs(xvoltspuqu) = mzmhctfyei vwnzvpmwoz (svgtfpzuap )
Positive
23 Jan 2025
Phase 1/2
Metastatic Colorectal Carcinoma
Third line
KRAS mutation | BRAF V600E mutation
39
kvlycjyoox(zupwszewkg) = mkovqgujbg njppwrmmfq (msgfletqte, 12.892 - 21.708)
Positive
23 Jan 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free